Intellia Therapeutics (NTLA) is involved in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies toward the clinic. It's real cutting-edge stuff and a sell side firm started fundamental coverage of the stock with an overweight rating (buy). Unfortunately, Intellia's charts tell me a different story. Let's check.
More from Stocks
Lopsided Market Returns
Despite the intraday reversal in Apple, Microsoft, Alphabet, Amazon, and Tesla, all helped the Nasdaq 100 outperform the other indexes as the small caps disappointed.
How to Trade MongoDB After Its Huge Upside Move
Let's check out the charts and indicators for clues.
This Value Portfolio of Lovable Losers Is Down But Not Out
With about six months to go, anything can happen for the 2023 Tax Loss Selling Recovery Portfolio.
Friday's Cheer Turns to Monday Drear
Even the bulls will likely agree that this market needs better participation and breadth.
As Palo Alto Networks Joins the S&P 500, Here's How to Play the Stock
This 'best-in-class' cybersecurity name was already hot, before the news.